

**SOUTH DAKOTA MEDICAID
PRIOR AUTHORIZATION CRITERIA**

Physician Administered Drugs, Vaccines, and Immunizations

Fecal Microbiota (Live) Rectal (Rebyota) – PA Criteria

HCPC: J1440

Rebyota is a live, fecal microbiota, rectal suspension indicated for the prevention of clostridiodes difficile infection (CDI) in individuals that are 18 years of age and older. It is covered by South Dakota Medicaid following prior authorization when the patient meets the following criteria:

- **Initial Therapy (must meet all):**
 - Therapy is prescribed by or in consultation with a gastroenterologist or infectious disease specialist
 - Individual has had a confirmed diagnosis of clostridiodes difficile infection as demonstrated by a positive stool test
 - Individual has had ≥ 2 relapses (initial episode and 2 recurrences) of CDI
 - Therapy is being utilized for prevention of additional CDI infections (contraindicated until individual has completed an approved treatment regimen)
 - Therapy will be administered within 24 to 72 hours of completing antibiotic treatment for current clostridiodes difficile infection
 - Individual has not previously received Rebyota, Vowst or prior fecal microbiota transplants within the last 2 years
 - Individual has failed therapy with pulsed dose fidaxomicin and bezlotoxumab (Zinplava)
 - Individual is ≥ 18 years of age
 - Approval duration: one dose
- **Continuation of Therapy: not permitted**